Suppr超能文献

组织型纤溶酶原激活剂(tPA)活性是2型糖尿病无症状下肢动脉硬化疾病的一种新型早期标志物。

Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes.

作者信息

Sahli David, Eriksson Jan W, Boman Kurt, Svensson Maria K

机构信息

Department of Medicine, Umeå University Hospital, Umeå, Sweden.

出版信息

Thromb Res. 2009 Mar;123(5):701-6. doi: 10.1016/j.thromres.2008.07.015. Epub 2008 Oct 21.

Abstract

INTRODUCTION

Lower extremity arterial disease (LEAD) is often one of the first signs of a generalized atherosclerotic disease in type 1 and type 2 diabetic subjects.

MATERIALS AND METHODS

We studied 143 diabetic subjects at 30-70 years of age, M/F 69/74, 74 with type 1 and 69 with type 2 diabetes, without previously known or suspected lower extremity arterial disease. The relationship between early asymptomatic lower extremity arterial disease and blood levels of HbA1c, lipids and fibrinolysis markers (tPA-activity, tPA mass, PAI-1 activity, tPA-PAI-1 complex) was assessed. In parallel, a group with non-diabetic subjects (n=80) was studied.

RESULTS

35 (24%) diabetic subjects were classified as having sign(s) of LEAD, defined as having at least one reduced peripheral blood pressure measurement, 28% in type 1 vs 20% in type 2 diabetic subjects (p=NS). In univariate logistic regression analyses age, glycemic level (HbA1c), male gender (only in type 1 diabetic subjects), hypertension and tPA activity (only in type 2 diabetic subjects) were positively associated with LEAD. When markers of fibrinolysis were entered into a multivariate model adjusting for age, hypertension, and HbA1c, only tPA activity remained independently associated with LEAD (p=0.01) and this was also found in type 2 diabetic subjects (p=0.05). In type 1 diabetic subjects the increase in odds ratio was non-significant.

CONCLUSIONS

Tissue plasminogen activator (tPA) activity may be an independent and early marker for asymptomatic lower extremity arterial disease in diabetic subjects, particularly in type 2 diabetes. Thus an altered fibrinolytic activity could be an early marker of atherosclerosis development in the lower extremities but the cause-effect relationship remains unclear.

摘要

引言

下肢动脉疾病(LEAD)通常是1型和2型糖尿病患者全身性动脉粥样硬化疾病的早期体征之一。

材料与方法

我们研究了143名年龄在30至70岁之间的糖尿病患者,男/女为69/74,其中74例为1型糖尿病,69例为2型糖尿病,既往无已知或疑似下肢动脉疾病。评估了早期无症状下肢动脉疾病与糖化血红蛋白(HbA1c)、血脂和纤维蛋白溶解标志物(组织型纤溶酶原激活物活性、组织型纤溶酶原激活物质量、纤溶酶原激活物抑制剂-1活性、组织型纤溶酶原激活物-纤溶酶原激活物抑制剂-1复合物)血液水平之间的关系。同时,研究了一组非糖尿病患者(n = 80)。

结果

35例(24%)糖尿病患者被归类为患有LEAD体征,定义为至少有一次外周血压测量值降低,1型糖尿病患者中为28%,2型糖尿病患者中为20%(p =无显著性差异)。在单因素逻辑回归分析中,年龄、血糖水平(HbA1c)、男性性别(仅在1型糖尿病患者中)、高血压和组织型纤溶酶原激活物活性(仅在2型糖尿病患者中)与LEAD呈正相关。当将纤维蛋白溶解标志物纳入调整年龄、高血压和HbA1c的多变量模型时,只有组织型纤溶酶原激活物活性与LEAD保持独立相关(p = 0.01),在2型糖尿病患者中也发现了这一点(p = 0.05)。在1型糖尿病患者中,比值比的增加无显著性意义。

结论

组织型纤溶酶原激活物(tPA)活性可能是糖尿病患者无症状下肢动脉疾病的一个独立且早期的标志物,尤其是在2型糖尿病中。因此,纤维蛋白溶解活性改变可能是下肢动脉粥样硬化发展的早期标志物,但因果关系仍不清楚。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验